The congenital myasthenic syndromes (CMS) are a diverse group of genetic disorders caused by abnormal signal transmission at the motor endplate, a special synaptic contact between motor axons and each skeletal muscle fi bre. Most CMS stem from molecular defects in the muscle nicotinic acetylcholine receptor, but they can also be caused by mutations in presynaptic proteins, mutations in proteins associated with the synaptic basal lamina, defects in endplate development and maintenance, or defects in protein glycosylation. The specifi c diagnosis of some CMS can sometimes be reached by phenotypic clues pointing to the mutated gene. In the absence of such clues, exome sequencing is a useful technique for fi nding the disease gene. Greater understanding of the mechanisms of CMS have been obtained from structural and electrophysiological studies of the endplate, and from biochemical studies. Present therapies for the CMS include cholinergic agonists, long-lived open-channel blockers of the acetylcholine receptor ion channel, and adrenergic agonists. Although most CMS are treatable, caution should be exercised as some drugs that are benefi cial in one syndrome can be detrimental in another.
Introduction
The congenital myasthenic syndromes (CMS) are a group of inherited disorders in which neuromuscular transmission is impaired at the motor endplate (a special synaptic contact between motor axons and each skeletal muscle fi bre) by one or more specifi c mechanisms (panel 1, appendix). The CMS have been recognised as clinical entities since the 1970s, after the autoimmune basis of myasthenia gravis and of the Lambert-Eaton myasthenic syndromes were fi rst described. The diff erent CMS were fi rst identifi ed by combined clinical, electrophysiological, and structural studies. Initially, the CMS were classifi ed according to the location of the mutant protein as presynaptic, synaptic basal laminaassociated, or post synaptic. The study of CMS gained further impetus in the early 1990s when Sanger sequencing was used to identify the gene sequence of the endplate associated proteins. Since 2011, whole-exome sequencing has accelerated the discovery of novel CMS and, to date, 20 CMS disease genes have been identifi ed (table 1, fi gure 1). The most common cause of CMS is defects in the acetylcholine receptor; the next most common cause is mutations that aff ect endplate development and maintenance. However, some CMS have been reported in only single cases.
In this Review we consider the factors that aff ect neuromuscular transmission at the endplate, the CMS identifi ed to date and their distinguishing features and pathogenesis, and discuss available therapies.
Diagnosis
A generic diagnosis of CMS can be made on the basis of onset at birth to early childhood, fatigable weakness especially aff ecting the ocular and other cranial muscles, a positive family history, and a decremental electromyographic response, defi ned as a greater than 10% decrease of the amplitude or area of the fourth, compared to the fi rst, evoked compound motor action potential, or an abnormal single-fi bre electromyographic response (panel 2). However, some CMS present later in life, the weakness can aff ect proximal and torso, rather than cranial, muscles, and the decremental electromyographic response might be detected only after prolonged subtetanic stimulation. Tests for antiacetylcholine receptor and anti-muscle-specifi c tyrosine kinase (MuSK) antibodies should be done in sporadic patients after the age of 1 year and in arthrogrypotic At the neuromuscular endplate, one molecule of acetylcholine released from the presynaptic terminal into the synaptic cleft binds to each of the two binding sites on the acetyl choline receptor on the postsynaptic membrane on the subjacent muscle fi bre. The rate constants of this binding approach the limit of diff usion, thus rapidly forming a doubly liganded complex with the receptor in which the ion channel remains closed. After a very short latency, the channel opens and it remains open for approximately 1 ms. After the channel returns to the doubly liganded closed state, acetylcholine rapidly dissociates from the binding sites and is cleared from the synaptic cleft by diff usion and hydrolysis by acetylcholinesterase. The combination of rapid dissociation and rapid clearance of acetylcholine ensures that the synaptic response is brief and that a response can be elicited in quick succession (appendix).
Electrical activation of a muscle fi bre requires that the amplitude of the endplate potential-the depolarisation of skeletal muscle fi bers caused by neurotransmitters binding to the postsynaptic acetylcholine receptor-should be greater than that of the threshold that triggers a propagated action potential. The diff erence between these two values-the depolarisation caused by the endplate potential (EPP) and the depolarisation needed to activate the voltage-gated Nav1·4 channels on the postsynaptic membrane-is known as the safety margin of neuromuscular transmission. 1 The amplitude of the EPP is a function of the number of acetylcholine molecules per synaptic vesicle, the number of synaptic vesicles released by a nerve impulse, and the effi cacy of packages (quanta) of neurotransmitter released from the endplate. Quantal effi cacy is determined by the spatial arrangement of the diff erent endplate components, the concentration and functional state of acetylcholinesterase in the synaptic space, the concentration and affi nity for acetylcholine, and the kinetic properties of the acetylcholine receptor, 1 as well as the concentration and kinetic properties of the Na v 1·4 sodium channels. 2 The mutated proteins in CMS can be involved in either the presynaptic, synaptic, or post-synaptic processes of the endplate.
See Online for appendix Review infants, even if the mother has no myasthenic symptoms to exclude autoimmune myasthenia.
The genetic diagnosis of a specifi c CMS is greatly helped when clinical and electromyographic studies point to a candidate gene (panel 3) . If a suffi cient number of aff ected and unaff ected relatives are available, linkage analysis can point to a candidate chromosomal locus. This approach works best in consanguineous populations and multiplex families. 3, 4 Tests for CMS-causing mutations in previously identifi ed CMS genes are now commercially available, but these are best used in a targeted manner based on specifi c phenotypes. Whole-exome sequencing has been used to identify novel CMS-causing mutations. This approach captures about 97% of the entire exome but reads only 75% of the exome with more than 20-times coverage. Analysis is improved if DNA from both parents and more than one aff ected family member is sequenced. Exome sequencing with bioinformatic analysis tools is still expensive, and the putative mutations must be confi rmed by Sanger sequencing. Exome sequencing analysis can miss pathogenic non-coding variants and large deletions or duplications that can be identifi ed by array-based comparative genomic hybridisation. 5 Also, synonymous variants that can cause exon skipping are often not registered. If a novel CMS disease gene is discovered, in-vitro expression studies with the genetically engineered mutant protein and structural studies of the neuromuscular junction can be used to confi rm its pathogenicity. 6 Special studies to investigate pathogenic mechanisms in novel CMS are listed in the appendix.
Presynaptic syndromes Choline acetyltransferase defi ciency
Choline acetyltransferase (ChAT) catalyses the synthesis of acetylcholine from acetyl coenzyme A and choline in cholinergic neurons. A diagnosis of ChAT defi ciency is suggested by sudden episodes of apnoea that can be provoked by stress, but sometimes have no apparent cause and can also occur in patients with few or no myasthenic symptoms. Some patients are apnoeic and hypotonic at birth, whereas others are normal at birth and develop apnoeic attacks during infancy or childhood. [7] [8] [9] [10] [11] However, apnoeic episodes are not limited to patients with ChAT defi ciency, and can also occur in patients with sodium-channel myasthenia 2 and with mutations in rapsyn. 12, 13 In some children with ChAT defi ciency, an apnoeic attack is followed by ventilatory failure for weeks.
14 A few patients never breathe spontaneously, and some develop cerebral atrophy from hypoxaemia.
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A clue to the identity of the disease gene came from the observation that subtetanic stimulation decreased the amplitude of the compound muscle action potential (CMAP)-the sum of several, almost simultaneous, muscle action potentials from several muscle fi bres in the same area-and of EPP to 50% below baseline (normal decrease is <30%), followed by slow recovery over 5-10 mins. A marked decrease of the CMAP amplitude after subtetanic stimulation also occurs in other CMS but is followed by recovery in less than 5 mins. The slow recovery implicated a defect in acetylcholine resynthesis and provided the clue to discovery of mutations in ChAT 15 (fi gure 2). The severity of this CMS has been associated with the position of the mutant residues in the atomic structural model of ChAT, which in experimental models can aff ect the level of expression, catalytic activity, and structural stability of the enzyme. 11 The most severe kinetic abnormalities are caused by mutations in the active-site tunnel of the enzyme, mutations close to the substrate-binding site, or mutations that exert their eff ect allosterically (fi gure 2).
Index cases Proportion (%)
Presynaptic 5·6%
Choline acetyltransferase defi ciency 18 5·1%
Paucity of synaptic vesicles and reduced quantal release* 1 0·3% Classifi cation based on a cohort of patients with CMS investigated at the Mayo Clinic between 1988 and 2014. In another series of 680 patients with CMS, the frequencies of mutations in choline acetyl transferase, ColQ, acetylcholine receptor subunits, rapsyn, and Dok7 were similar to those investigated at the Mayo Clinic. 3 CMS=congenital myasthenic syndromes. *No gene defect identifi ed. †Defects in ALG2 and ALG14 and in the mitochondrial citrate synthesis carrier were identifi ed at other medical centres. 
Review
These mutations compromise the safety margin of neuromuscular transmission through incomplete fi lling of the synaptic vesicles with acetylcholine. Parents of children with acute apnoeic attacks should be instructed in the use of a portable respirator and an apnoea monitor at home.
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SNAP25B defi ciency
SNAP25B is one of the three SNARE proteins essential for initiation of synaptic vesicle exocytosis at the endplate and the central synapse. SNAP25B defi ciency was reported in an African-American patient who was hypomotile in utero and stiff and cyanotic at birth, requiring oxygen therapy, and had multiple joint contractures. She learned to walk with a walker after age 7 years. She has periods of staring and unresponsiveness, her EEG showing generalized spike and wave discharges that did not change during the staring spells. At age 11 years, she has fatigable weakness, fl uctuating eyelid ptosis, paretic and ataxic gait, spastic and ataxic dysarthria, and her development is at the level of a child aged 3-4 years. She harbours a de-novo dominantnegative Ile67Asn mutation in SNAP25B. In-vitro endplate studies show a reduced number of acetylcholinecontaining quanta released from the nerve terminal by each nerve impulse, and a reduced miniature endplate potential (MEPP) frequency. Therapy with amifampridine improved the patient's strength but not her ataxia.
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Synaptotagmin 2 defi ciency
Synaptotagmin 2 is a synaptic vesicle-associated calcium sensor. Dominant mutations in the calcium-binding domain of synaptotagmin 2 reported in two kinships were associated with childhood-onset foot deformities, fatigable muscle weakness, reduced-to-absent tendon refl exes, and low amplitude compound motor action potentials with post-exercise facilitation.
17
Synaptic basal lamina-associated syndromes
Endplate acetylcholinesterase defi ciency due to mutations in COLQ The isoform of acetylcholinesterase at the endplate is an asymmetric enzyme composed of one, two, or three homotetramers of globular catalytic subunits anchored to the synaptic basal lamina by ColQ, a triple-stranded collagenic tail (fi gure 3). 18, 19 Mutations in COLQ result in prolonged synaptic currents and action potentials owing to the extended residence of acetylcholine in the synaptic space. 20 The nerve terminals are abnormally small, which curtails the number of quanta available for release, and some junctional folds are degenerating because the prolonged synaptic currents allow excessive Ca 2+ ingress into the junctional folds. 18, 20 Mutations have been identifi ed in each of the three ColQ domains (fi gure 3) [21] [22] [23] Mutations in the N-terminal domain prevent the collagen domain from associating with the catalytic subunits; mutations in the collagen domain Review truncate and prevent assembly of the triple-helical collagen domain; and most mutations in the C-terminal domain reduce ColQ expression or prevent the triple helical assembly of the collagen domain. Severely aff ected patients with mutations that abolish enzyme activity present in infancy. 18, 20 Less severely aff ected patients with residual enzyme activity present in childhood and become disabled later in life. The weakness can aff ect all voluntary muscles but can spare the ocular muscles, and in few patients it has a limb-girdle distribution. Treatment with ephedrine 22, 23 or albuterol 24, 45 is benefi cial, but the eff ects develop gradually, over several months or longer 25 and the mechanism by which adrenergic agonists improve the symptoms is not understood.
Laminin-β2 defi ciency
Laminin β2, encoded by LAMB2, is highly expressed in the basal lamina of the eye and kidney, and at the endplate. At the endplate, laminin β2 is involved in accurate alignment of the nerve terminal with the postsynaptic region and diff erentiation of the presynaptic region. Only one report describes this CMS. A 20-year-old-woman had renal and ocular malformations (Pierson syndrome) and a CMS due to two frameshift mutations in LAMB2. 26 Neuromuscular transmission was compromised by reduced quantal release evoked by nerve stimulation. The nerve terminals were small, similar to endplate acetylcholinesterase defi ciency, which accounts for the decreased quantal release. The reduced miniature EPP amplitude was attributed to the paucity and poor development of the junctional folds.
Defects in the acetylcholine receptor Muscle nicotinic acetylcholine receptor
Most CMS stem from molecular defects in the muscle nicotinic acetylcholine receptor, 6 an integral membrane protein with the subunit composition α 2 βδε at the adult endplate or α 2 βδγ at the foetal endplate and extrajunctional regions. The genes encoding the α (CHRNA1), δ (CHRND), and γ (CHRNG) subunits are at diff erent loci on chromosome 2q, and those encoding the β (CHRNB) and ε (CHRNE) subunits are at diff erent loci on chromosome 17p. At the endplate, the acetylcholine receptor is concentrated on the crests of the junctional folds.
Each acetylcholine receptor has two solvent accessible acetylcholine-binding pockets located at the α/ε (or α/γ) and α/δ subunit interfaces (appendix p 6). Residues from seven distinct regions of the primary sequences of each subunit pair converge to form the acetylcholine binding pocket: three regions originate from the α subunit and four from the δ, ε, or γ subunits. 27 Because each acetylcholine-binding site contains diff erent non-α subunits, the rates of acetylcholine association and dissociation diff er at each site, resulting in distinct agonist binding affi nities. 28 The extent to which the binding affi nities diff er depends on the species; for an adult human acetylcholine receptor the affi nities diff er by roughly fi ve-fold, with the α/δ site showing high affi nity and the α/ε site showing low affi nity. 29 The mechanisms of acetylcholine receptor activation are described and discussed in the appendix.
Primary acetylcholine receptor defi ciency
These CMS can result from recessive missense, nonsense, or splice site and promoter region mutations in any of the acetylcholine receptor subunits, but most occur in the ε subunit (fi gure 4). 30 The high frequency of mutations in the ε subunit compared with other subunits has been attributed to phenotypic rescue by substitution of the foetal γ subunit for the defective ε subunit. 31, 32 Despite this phenotypic rescue, the endplate acetylcholine receptor complement is decreased to about 10% of normal, and the synaptic response to acetylcholine, 
Autophagic myopathy GFPT1, DPAGT1
Stridor and vocal cord paralysis in neonates or infants Dok-7
Nephrotic syndrome and ocular malformations Laminin β2
Association with seizures or intellectual disability DPAGT1
Association with epidermolysis bullosa simplex and muscular dystrophy Plectin
Review refl ected by the low amplitude of the miniature EPP and miniature endplate current, is markedly decreased. Evoked quantal release is increased and partly compensates for the acetylcholine receptor defi ciency. 33 Single-channel patch-clamp record ings from patient endplates reveal low-amplitude, long-duration channel openings, which are typical of the fetal acetylcholine receptor. The synaptic contacts consist of many small regions over an extended length of the fi bre surface, but the structural integrity of the presynaptic and postsynaptic regions is preserved.
Nearly all patients have eyelid ptosis, oculoparesis that often becomes fi xed, and variable but frequently moderate-to-severe limb muscle weakness. Most patients with low-expressor mutations in the ε subunit respond to cholinergic agonists and some derive additional benefi t from salbutamol. 34, 35 Individuals harbouring null mutations in both alleles of CHRNA1, CHRNB, or CHRND cannot be rescued because no substituting subunits exist and hence these individuals probably die in utero. Patients with heterozygous or homozygous low-expressor mutations in the non-ε subunits are severely aff ected and have high mortality in infancy or early childhood.
Kinetic defects in acetylcholine receptor
Slow-channel syndrome
This syndrome is caused by dominant mutations in the ligand-binding or pore domains of the acetylcholine receptor (appendix) that result in prolonged synaptic currents and action potentials. The reported mutations in the ligand-binding domain enhance affi nity for acetylcholine and slow its dissociation rate from the doubly-liganded receptor, whereas most mutations in the pore domain enhance receptor activation after agonist binding. 36 Both mechanisms prolong the single-channel currents (appendix p 7), endplate currents, and EPPs, while mutations in the pore domain also cause spontaneous channel openings. Similar to endplate acetylcholinesterase defi ciency, the prolonged EPP triggers a repetitive compound motor action potential (appendix p 7), that is enhanced by edrophonium. Also, 
Choline, mmol/L Figure 2: Choline acetyltransferase (ChAT) (A) Subtetanic stimulation in a patient with ChAT defi ciency rapidly decreases the endplate potential (the depolarization of skeletal muscle fi bers caused by neurotransmitters binding to the postsynaptic acetylcholine receptor), which returns to the baseline slowly over more than 10 min. Amifampridine, which increases quantal release, accelerates the decline of the endplate potential, whereas a low Ca²+/high Mg²+ solution reduces quantal release and prevents the abnormal decline of the endplate potential. (B) Positions of mutated residues (shown in red) in active-site tunnel of ChAT (red asterisk). (C) Kinetic landscapes, obtained from reaction velocities over a range of acetyl coenzyme A and choline concentrations of wild-type ChAT and of the mutant enzymes in the active site tunnel of ChAT. Compared with the wild-type, the Met202Arg mutant, which is closest to the catalytic His442 residue (shown in blue in panel B), has the greatest eff ects on the reaction velocity. The Thr553Asn and Ala557Thr mutations, which are further away from the catalytic site (His442 shown in blue) than Met202Ag, also decrease the reaction velocity but to lesser extents. Panel A is reproduced from reference 30 by permission of Nature Publishing Group; Panels B and C are reproduced from reference 11 by permission of Wiley. Pt=patient.
Review during repetitive stimulation, successive prolonged EPPs progressively depolarise the postsynaptic mem brane, causing a depolarisation block. The pro longed and spontaneous openings of the acetylcholine receptor channel result in Ca² + accumulation in the postsynaptic region, 37, 38 leading to endplate myopathy (appendix p 7). The safety margin of neuromuscular transmission is compromised by the depolarisation block of the action potential, desensitisation of the acetylcholine receptors at physiological rates of neuromuscular activity, and by endplate myopathy that causes loss of acetyl choline receptor from the junctional folds and widens the synaptic space allowing for acetylcholine loss by diff usion.
The slow-channel syndrome usually presents in the fi rst decade of life, but severely aff ected patients present in the neonatal period. There is severe involvement of the cervical, scapular, and dorsal forearm muscles. The ocular muscles are usually spared. Some patients have mild, asymmetric ptosis.
Fast-channel syndrome
This syndrome is caused by a recessive mutation in one allele of an acetylcholine receptor subunit, accompanied by a null or low-expressor mutation, or rarely by another fast-channel mutation, on the other allele 30 (appendix). This is the physiological opposite of the slow-channel syndrome in that the endplate currents decay abnormally fast, the channel openings are abnormally brief and the amplitude of the synaptic currents and potentials is reduced, owing to a decreased probability that the acetylcholine receptor channel is opened by physiological concentrations of acetylcholine (appendix p 8).
The causative mutations are in diff erent domains and subunits of acetylcholine receptor (appendix p 8) and exert their eff ects by diff erent mechanisms. In the extra cellular domains, εPro121Leu 39 and εTrp55Arg 40 decrease affi nity for acetylcholine, whereas αVal132Leu, 41 αVal188Met, 42 and δLeu42Pro 43 decouples agonist binding from channel opening. In the third transmembrane domain, αVal285Ile decreases gating effi ciency. 44 In the long cytoplasmic loop of the ε subunit, Asn436del shortens channel openings by reducing the stability of the diliganded receptor, 45 and c.1254ins18 46 and Ala411Pro ColQ by electrostatic interaction with anionic residues in the synaptic basal lamina. Electron cytochemical localisation of acetylcholinesterase in a healthy control participant (C) and in an acetylcholinesterase-defi cient patient (D), in whom there is no reaction for acetylcholinesterase at the endplate.
Review
No clinical clues point to the diagnosis of a fast-channel syndrome. In such patients, in-vitro microelectrode studies of the neuromuscular junction and single-channel patchclamp studies are required to defi ne the pathomechanism and appropriate therapy The clinical consequences are severe when the pathogenic mutation is located at or near the agonist binding site, 40 aff ects coupling of agonist binding to gating, 41 or is located in a transmembrane domain. 44 The phenotype is less severe when the mutation is in the long cytoplasmic loop of the ε subunit. 46, 47 
Defects in endplate development and maintenance
To date, mutations in genes that encode proteins essential for endplate development and maintenance, such as MUSK, AGRN, LRP4, DOK7, and RAPSN, have been detected patients with CMS The products of these genes are components of a signalling network essential for endplate development and maintenance. Agrin, the product of AGRN, is secreted into the synaptic space by the nerve terminal and binds to the lipoprotein-related protein LRP4 in the postsynaptic membrane. The agrin-LRP4 complex binds to and activates the receptor tyrosine kinase MuSK. This binding enhances MuSK phospho rylation and leads to clustering of LRP4 with MuSK. Activated MuSK phosphorylates Dok-7; this leads to recruitment of two adaptor proteins, Crk and CrkL, that serve as downstream activators of Dok-7. Full activation of MuSK results in activation of rapsyn, which induces rapsyn to concentrate acetylcholine receptor on the postsynaptic membrane, enhances synapse-specifi c gene expression in postsynaptic nuclei, and promotes post synaptic diff erentiation. Clustered LRP4, in turn, promotes diff erentiation of motor axons. The agrin-LRP4-MuSK-Dok-7 signalling system is also essential for maintaining the structure of the adult neuromuscular junction.
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Agrin defi ciency
Three reports describe a CMS caused by defects in agrin. In one report, a 42-year-old woman and her 36-year-old brother had had eyelid ptosis and mild weakness of the facial and limb-girdle muscles since early childhood. 50 They carry a homozygous missense mutation (Gly1709Arg) in the laminin G-like 2 domain needed for MuSK activation. The endplates showed no decrease of acetylcholine or agrin expression, but were misshapen or regenerating. Some postsynaptic regions were denuded of their nerve terminal but the ultrastructure of the junctional folds was preserved. In vitro expression studies revealed no eff ect on MuSK activation by mutant agrin; therefore, the Gly1709Arg mutation perturbs endplate maintenance without preventing postsynaptic diff erentiation. The second report describes a severe CMS in a 39-year-old man caused by two heteroallelic mutations: Gln353X in the N-terminal region and Val1727Phe located in the second laminin G-like domain of agrin. 51 In vitro, Gln353X abolished agrin expression and Val1727Phe substantially reduced agrin-induced acetylcholine receptor clustering in C2 muscle cells. The synaptic contacts were dispersed and fragmented, the postsynaptic junctional folds were sparse and poorly developed, the nerve terminals were small, and the junctional cytoplasm had degenerative changes.
A third report is of fi ve patients in three kinships with a distinct phenotype associated with wasting that fi rst aff ected the lower and later the upper limbs, with fat Figure 4 : Endplate acetylcholine receptor defi ciency Low-expressor and null mutations reported in the acetylcholine receptor α, β, δ, and ε subunits. Most mutations occur in the ε subunit. Ultrastructural localisation of acetylcholine receptor with peroxidase-labeled α-bungarotoxin at an endplate from a healthy control participant(B) and from a patient homozygous for 553del7 in the ε subunit (C). Panel A is reproduced from reference 30 by permission of Nature Publishing Group.
replacing the posterior leg compartments, sparing of the axial and cranial muscles, and slow progression of weakness. 52 The age at onset ranged from birth to early adulthood. In two siblings in the fi rst kinships the entire AGRN gene was deleted at one allele and the second allele had an N-terminal Gly765Ser mutation, which reduced agrin-induced acetylcholine receptor clustering in C2 muscle cells in vitro. Two siblings in the second kinship were heteroallelic for an N-terminal Asn105Ile mutation and a frameshifting nucleotide duplication mutation, c.1362dup; p.Ser455Glnfs*8. The one patient in the third kinship was homozygous for a Glu1871Arg mutation in the C-terminal region of AGRN. Thus, in each case the phenotype was determined by a single missense mutation. Acetylcholine receptor expression at the endplates was not noticeably reduced, but neuromuscular transmission was not examined in any patient.
LRP4 defi ciency
One study 53 identifi ed heteroallelic Glu1233Lys and Arg1277His mutations at the edge of the third betapropeller domain of LRP4 in a 14-year-old girl. Both mutations decrease binding affi nity of LRP4 for both MuSK and agrin. The patient had a respiratory arrest at birth, delayed motor development, and fatigable weakness of the limb-girdle muscles.
MuSK defi ciency
In the past decade, fi ve reports have described CMS caused by mutations in MUSK (fi gure 5). MuSK defi ciency presents at birth or early life with eyelid ptosis or respiratory distress. [54] [55] [56] [57] [58] Subsequently, it aff ects the ocular, facial, and proximal limb muscles, and in some kinships the bulbar muscles as well. Structural studies in human beings and transgenic mice 59 show extensive remodelling of the endplates due to recurrent cycles of focal denervation and reinnervation. No clear genotypephenotype correlations have been observed.
Dok-7 defi ciency
The in-vitro observation that Dok-7 is a muscle-intrinsic activator of MuSK 60 prompted a search for CMS caused by mutations in DOK7. Many mutations were detected in DOK7, [61] [62] [63] [64] [65] but the frameshifting c.1124_1127dupTGCC in exon 7 emerged as a common variant. Other mutations prevent Dok-7 from associating with and becoming activated by Crk1 and Crk1L. The clinical course of Dok-7 defi ciency can be from mild to severe. Although no consistent phenotype-genotype correlations have been detected, all patients have limb-girdle weakness, with lesser facial and cervical muscle involvement; 66 a few have severe bulbar weakness and signifi cant oculoparesis. 63 Some were initially misdiagnosed as having limb-girdle muscular dystrophy. Type 1 fi bre preponderance, type 2 fi bre atrophy, mild myopathic changes, and presence of target formations are associated features. The endplates in all patients consist of one to many small synaptic contacts. Impaired maintenance of the endplates is evidenced by ongoing destruction and remodelling (fi gure 6). Neuromuscular transmission is compromised by the decreased quantal content of the EPP and the reduced miniature EPP amplitude.
63
Rapsyn defi ciency
Rapsyn concentrates and anchors the acetylcholine receptor in the postsynaptic membrane 67 and is needed for the development of the junctional folds. 12 Distinct regions of rapsyn have diff erent functions: the myristoylated N-terminal region links rapsyn to the post synaptic membrane; seven tetratricopeptide (TPR1-7) repeats are important for rapsyn selfaggregation and to bind to the cytoplasmic domain of MuSK; a coiled-coil domain interacts with long-cytoplasmic loops of the acetylcholine receptor subunits; and a C-terminal domain binds to β dystro glycan, which links rapsyn to the actin cytoskeleton 67, 68 (fi gure 7). Cryoelectron tomography studies show that rapsyn and the acetylcholine receptor form a complex, with up to three rapsyn dimers contacting the cytoplasmic domain of each acetylcholine receptor. 69 Most patients with rapsyn defi ciency present in the fi rst year of life, with a few presenting in childhood or adult life. 13 Arthrogryposis at birth and other congenital malformations occur in nearly a third of patients. 12, 13, 70 Intercurrent infections or fever can trigger respiratory crises, resulting in anoxic encephalopathy. 12 Review clinical features can suggest autoimmune myasthenia gravis but the ocular ductions are intact in most patients. 13, 73 Many synaptic contacts are present on individual muscle fi bres (fi gure 7). The endplate acetylcholine receptor defi ciency is milder than in primary acetylcholine receptor defi ciency, 70 but the junctional folds are not well diff erentiated (fi gure 7).
Patients of European or Indian subcontinent origin harbour a common Asn88Lys mutation in RAPSN. 73 Other mutations have been detected in the promoter region or throughout the entire open reading frame of RAPSN. Diff erent mutations, hinder rapsyn selfassociation or binding to acetylcholine receptor, impede agrin-MuSK-LRP4-mediated clustering of acetylcholine receptor, or decrease rapsyn expression. 12, 74 There are no genotype-phenotype correlations except that oriental Jewish patients with a homozygous E-box mutation (c.38A>G) have a mild phenotype with ptosis, prognathism, severe masticatory and facial muscle weakness, and hypernasal speech. 75 
Congenital defects of glycosylation
Glycosylation increases solubility, folding, stability, assembly, and intracellular transport of nascent peptides. O-glycosylation occurs in the Golgi apparatus, with addition of sugar residues to the hydroxyl groups of serine and threonine residues; N-glycosylation occurs in the endoplasmic reticulum in sequential reactions that link the amino group of asparagine residues with a core glycan composed of two glucose, nine mannose, and two N-acetylglucosamine (GlcNAc) moeties. 76, 77 Defects in four enzymes that catalyse glycosylation have been found to cause CMS: GFPT1 (glutamine fructose-6-phosphate transaminase), 4 ,78 DPAGT1 (dolichyl-phosphate [UDP-Nacetylglucosamine] N-acetylgluco saminephospho transferase 1), 79, 80 ALG2 (alpha-1,3-mannosyl transferase), and ALG14 (UDP-N-acetylglucosaminyltransferase subunit). 81 Tubular aggregates of the sarcoplasmic reticulum seen with microscopy of muscle fi bres are a phenotypic clue to the diagnosis, but these are not present in all patients. Because glycosylated proteins are present at all endplate sites, neuromuscular transmission is compromised by the combination of presynaptic and postsynaptic defects.
Defects in GFPT1
GFPT1 regulates the entry of glucose into the hexosamine pathway, and hence the formation of precursors for N-linked and O-linked protein glycosylation. CMS caused by defects in GFPT1, causing limb-girdle muscle weakness that was responsive to pyridostigmine, was reported in 16 patients in 2011. 4 A subsequent study of 11 patients revealed slow progressive weakness in ten patients; one patient with mutations disrupting the muscle-specifi c exon of GFPT1 never moved in utero, was arthrogrypotic at birth, and was bedridden and tube-fed at age 8 years. This patient has a severe myopathy with numerous dilated and degenerating membrane bound vesicles, autophagic vacuoles, and apoptotic nuclei identifi ed by electron microscopy. 78 Muscle specimens from six of nine patients with less severe forms of the disease showed tubular aggregates of the sarcoplasmic reticulum. Electron Review microscopy showed abnormally small endplate regions and poorly developed junctional folds. In-vitro electrophysiology studies showed a decreased synaptic response to acetylcholine and decreased acetylcholine release in the most severely aff ected patient. The observation that many endplates in this syndrome are underdeveloped implicates hypoglycosylation and altered function of endplateassociated glycoproteins, such as MuSK, agrin, and dystroglycans.
Defects in DPAGT1
DPAGT1 catalyses the fi rst step of N-linked protein glycosylation. DPAGT1 defi ciency results in impaired N-linked glycosylation of many proteins distributed throughout the body, but in the fi rst fi ve patients to be reported with CMS harbouring DPAGT1 mutations, only neuromuscular transmission was adversely aff ected. This was speculated to be due to decreased acetylcholine receptor expression at the endplate, although the patient endplates were not analysed. 79 Another study of two siblings and a third patient with DPAGT1 defi ciency extended the phenotypic spectrum of the disease. 80 These patients have moderately severe weakness and intellectual disability. The siblings responded poorly to pyridostigmine and amifampridine; the third patient responded partly to pyridostigmine and salbutamol. Whole-exome sequencing showed that the siblings harboured a Met1Leu mutation that decreased DPAGT1 expression and a His375Tyr mutation, which decreased DPAGT1 activity. The third patient carries a Val264Met mutation that abolishes enzyme activity and a synonymous Leu120Leu mutation that profoundly augments exon skipping, resulting in many skipped and few non-skipped alleles and reduced expression of the wild-type protein. Intercostal muscle studies in these patients showed fi bre type disproportion with the mean diameter of the type 1 fi bres less than 50% of the diameter of type 2 fi bres, small tubular aggregates, and autophagic vacuolar myopathy. Electron microscopy showed that 6 of the 62 imaged endplate regions were degenerating and most endplates had small presynaptic and postsynaptic regions. Evoked acetylcholine release, postsynaptic response to acetylcholine, and endplate acetylcholine receptor concentration were all decreased to about 50% of normal. Immunoblots of muscle extracts with two antibodies detecting glycosylated, non-specifi c proteins showed decreased or absent glycosylation of several proteins, including STIM1, a sarcoplasmic reticulumassociated calcium sensor that operates in concert with the calcium release-activated, calcium channel protein ORAI1 on the plasma membrane to homoeostatically regulate the sarcoplasmic reticulum calcium concentration. 81 Because mutations in STIM1 cause a tubular aggregate myopathy, 82 STIM1 hypo glycosylation might be a cause of the tubular aggregates in muscle in N-glycosylation disorders.
Defects in ALG2 and ALG14
ALG2 catalyses the second and third committed steps of N-glycosylation. ALG14 forms a multiglycosyltransferase complex with ALG13 and DPAGT1 and thus contributes to the fi rst committed step of N-glycosylation. In one family, four aff ected siblings presenting with myasthenic symptoms in early childhood were homozygous for an insertion-deletion mutation. In another family, two sisters with myasthenic symptoms since around age 7 years carried heteroallelic Pro65Leu and Val68Gly mutations in ALG14. Another unrelated 4-year-old boy was homozygous for a low-expressor Val68Gly mutation. Endplate ultrastructure and parameters of neuromuscular transmission were not investigated in this study.
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Other myasthenic syndromes
PREPL deletion syndrome
The hypotonia-cystinuria syndrome is caused by recessive deletions in both SLC3A1 and PREPL on chromosome 2p21. The major clinical features are type A cystinuria, growth hormone defi ciency, muscle weakness, ptosis, and poor feeding. Isolated PREPL defi ciency has not been investigated in detail. A female patient presented at birth with marked hypotonia, eyelid ptosis and facial and bulbar muscle weakness. She and her mother harboured a heterozygous deletion at the 2p21 chromosomal locus involving the SLC3A1 and PREPL genes suggesting the cystinuria-hypotonia syndrome, but she had no cystinuria. Her father carried a heterozygous nonsense mutation in PREPL; hence her phenotype was determined by the paternal mutation. An edrophonium injection increased her strength transiently and she responded to pyridostigmine during infancy. 84 PREPL expression was absent from the patient's muscle and endplates. Further endplate studies revealed decreased evoked acetylcholine release and small miniature EPPs, despite normal endplate acetylcholine receptor expression. 84 Because PREPL is an essential activator of the clathrin-associated adaptor protein 1 (AP1), 85 which is needed by the vesicular acetylcholine transporter to fi ll the synaptic vesicles with acetylcholine, 86 the reduced miniature EPP is attributed to a decreased vesicular content of acetylcholine. The cause of the reduced evoked quantal release remains undefi ned.
Plectin defi ciency
Organelle and tissue-specifi c isoforms of plectin, encoded by PLEC, crosslink intermediate fi laments to their targets in diff erent tissues and thereby provide cytoskeletal support. Defects in plectin can cause epidermolysis bullosa simplex, 87 muscular dystrophy, 88, 89 and a myasthenic syndrome. 90, 91 The muscular dystrophy is caused by loss of cytoskeletal support of the muscle fi bre organelles, which become dislocated within the fi bre, and of the sarcolemma, resulting in many small defects that allow calcium ingress into the fi bres. 91 The two patients investigated by us harbour Glyn2057X and Arg2319X mutations, respectively, Review and a common c.12043dupG mutation 90, 91 Both patients had epidermolysis bullosa simplex since infancy and later developed a progressive myopathy, a CMS that was refractory to pyridostigmine, a decremental electromyographic response on repetitive nerve stimulation, and half-normal amplitude of mini ature EPPs, attributed to degeneration of the junctional folds with loss of acetylcholine receptor and altered endplate geometry.
Defects in sodium channels
This CMS was detected in a 20-year-old woman who had brief and abrupt attacks of muscle weakness and respiratory arrest since birth that caused an anoxic encephalopathy. 2 Evoked quantal release from the nerve terminal and the synaptic response to the released quanta were normal, but normal amplitude EPP failed to generate muscle action potentials, pointing to a defect in action potential generation. Mutation analysis of SCN4A, the gene encoding the Na v 1·4 sodium channel, revealed two mutations (Ser246Leu in the S4/S5 linker in domain I and Val1442Glu in S4/S5 linker in domain IV). Na v 1·4 expression at the endplates was normal. Expression studies of the Val1442Glu sodium channels in HEK cells revealed abnormally rapid decay of the Na + current in response to short depolarizations near the resting membrane potential (fast inactivation) and enhanced decay of the Na + current on high frequency stimulation for seconds or minutes (use-dependent inactivation). The Ser246Leu mutation had only minor kinetic eff ects and is probably a benign mutation. The safety margin of neuromuscular transmission is compromised because most Na v 1·4 channels are inexcitable in the resting state. 
Myasthenias associated with congenital myopathies
Eyelid ptosis, ophthalmoparesis, weakness of facial muscles, exercise intolerance, decremental electromyographic response, and response to pyridostigmine have been documented in some patients with centronuclear myopathies caused by mutations in amphiphysin (BIN1), 92 myotubularin (MTM1), 93 dynamin 2 (DNM2), 94 and in other patients with centronuclear myopathies with no identifi ed mutations. 95 Knockdown of MTM1 or DNM2 in zebrafi sh causes decreased spontaneous and touch-evoked movements that are dramatically increased in response to edrophonium. 93, 94 Detailed investigation of neuro muscular transmission in a 39-year-old man with centronuclear myopathy with myasthenic symptoms, but no identifi ed mutations, showed endplate remodelling, mild endplate acetyl choline receptor defi ciency, simplifi ed postsynaptic regions, a 60% reduction of the miniature EPP amplitude, and a 40% decrease of evoked acetylcholine release attributed to a decreased number of synaptic vesicles. 95 Two patients, a 19-year-old woman and a 7-year-old boy with a congenital myopathy caused by tropomyosin 3 defi ciency, had mild abnormalities on single fi bre EMG suggesting a defect of neuromuscular transmission. 96 Finally, two siblings, aged 9 and 7 years, harboring mutations in RYR1 (encoding ryanodine receptor 1) had fatigable ptosis as well as fatigable facial and general weakness suggesting myasthenia since infancy. 97 Pyridostigmine therapy initially improved their symptoms but the response was unsustained. Muscle specimens showed atrophy of type 1 and, to a lesser extent, of type 2 fi bers, with occasional loss of mitochondria and myofi brillar degeneration in central fi ber regions. EMG studies revealed no defect of neuromuscular transmission.
Myasthenic symptoms associated with defects in the mitochondrial citrate carrier
The mitochondrial protein SLC25A1 mediates the exchange of mitochondrial citrate/isocitrate with cytosolic maleate, which is cleaved to form acetyl-CoA and oxaloacetate by ATP-citrate lyase. Mutations of SLC25A1 were shown to interfere with brain, eye and psychomotor development. 98 Exome sequencing of two siblings with CMS and intellectual disability born to consanguineous parents revealed homo zygous Arg247Gln mutation in SLC25A1. Molecular studies indicated the mutation impairs the transport activity of the enzyme, and knockdown of SLC25A1 orthologues in zebrafi sh hindered motor axons from innervating muscle fi bres 99 A third patient, an 18-month-old girl, harboring heteroallelic Arg282His and Gly130Asp mutations in SLC25A1, also had myasthenic symptoms as well as hypoplastic optical nerves, agenesis of the corpus callosum, and 2-hydroxyglutaric aciduria. 98 
Available therapies
Current therapies for CMS include cholinergic agonists, namely pyridostigmine and amifampridine, long-lived open-channel blockers of the acetylcholine receptor ion channel such as fl uoxetine and quinidine, and adrenergic agonists, such as salbutamol and ephedrine.
Pyridostigmine acts by inhibiting acetyl cholinesterase in the synaptic basal lamina, which increases the number of acetylcholine receptors activated by a single quantum. Amifampridine increases the number of acetylcholine quanta released by each nerve impulse. Alone, and especially in com bination, these agonists increase the amplitude of the endplate potential and thereby meet the safety margin of neuromuscular transmission. Therefore, they are benefi cial in patients with endplate acetylcholine-receptor defi ciency and those with fastchannel syndromes, in which the safety margin of transmission is compromised by a decreased synaptic response to acetylcholine and an abnormally fast decay of the synaptic current. Fluoxetine and quinidine are long-lived open-channel blockers of the acetylcholine receptor used in the treatment of the slow-channel syndrome. By shortening the duration of the prolonged synaptic currents, they prevent a depolarisation block and desensitisation of acetylcholine receptor at physiological rates of stimulation and mitigate the cationic overloading Review of the postsynaptic region that causes degeneration of the junctional folds and alters the endplate geometry. Salbutamol and ephedrine were empirically eff ective in CMS caused by mutations in the ColQ component of acetylcholinesterase, Dok-7, and laminin β2, and in some patients harbouring low-expressor mutations of the acetylcholine receptor. The mechanisms by which these open-channel-blockers improve neuromuscular transmission are not understood.
Drugs that benefi t one type of CMS can be ineff ective or harmful in another type. For example, patients harbouring low-expressor or fast-channel mutations in acetylcholine receptors show improvement with choli nergic agonists, whereas the condition of patients with slow-channel mutations in acetylcholine receptors deter iorates on these drugs. Patients harbouring mutations in Dok-7 get rapidly worse with treatment with cholinergic agonists but improve with treatment with adrenergic agonists. Therefore a molecular diagnosis is essential to inform the choice of therapy. Finally, the cholinergic agonists pyridostigmine and amifampridine exert their eff ect as soon as the drug is absorbed, whereas the adrenergic agonists and the acetylcholine-receptor-channel blockers act more slowly over days, weeks, or months. Table 2 summarises the pharmacotherapy of the recognised CMS.
Conclusions and future directions
In the absence of a clear cause for many CMS, identifi cation of their molecular bases with in-depth clinical evaluation combined with electrophysiological and morphometric analyses of the patient endplates, is essential. With the introduction of gene cloning and the sequencing of complementary DNAs, the candidate gene approach has provided a powerful complement to these analyses. When a variant in a candidate gene is identifi ed, the goal is to understand its pathogenicity. This could be achieved by incorporating the wild type and mutant genes into a heterologous expression system and then assessing the level of expression of the mutant protein and its functional properties by methods such as patchclamp studies, to dissect the kinetic eff ects of acetylcholine receptor mutants, and enzyme assays of the wild type and mutant species of ChAT, DPAGT1, and acetylcholinesterase. These approaches have demonstrated that the CMS are caused by a diversity of disease targets and molecular mechanisms, which together guide individualised therapy.
Despite the power of the candidate gene approach, in some CMS the disease gene has remained elusive. For these CMS, whole-exome sequencing, which has become available in the past 3 years, proved to be a lodestone to discovery of unsuspected defects in genes encoding proteins involved in protein glycosylation. The power of this approach is enhanced if many family members, and especially trios, are analysed, and interpretation of the results is greatly helped by phenotypic clues. Although whole-exome sequencing fails to identify large scale duplications or deletions, these can now be detected by micro array-based comparative gene hybridisation. A future approach will be the use of custom-made microarrays designed to detect mutations in previously identifi ed CMS disease genes. A drawback of this method
Search strategy and selection criteria
PubMed was searched for articles published on congenital myasthenic syndromes between Jan 01 2004 and August 31 2014 with no language restrictions. The primary search term was: "congenital myasthenic syndrome". The secondary search terms were: "acetylcholine receptor"; "choline acetyltransferase"; "ColQ"; "laminin beta-2"; "agrin"; "LRP4"; "MuSK"; "Dok-7"; "rapsyn"; "GFPT1"; "DPAGT1"; "ALG2"; "ALG14"; "Prepl"; "plectin"; "centronuclear myopathies"; "Na v 1·4 channel"; "Synaptotagmin"; and "SNAP25". The authors also searched their own reprint fi les, clinical histories of their patients, and data fi les of their own research studies. Pyridostigmine; amifampridine also helps; salbutamol can help if refractory to above 34, 35 ..
Slow-channel syndrome Quinine, quinidine, or fl uoxetine 34 Avoid pyridostigmine and amifampridine Fast-channel syndrome Pyridostigmine and amifampridine 39, 40 Avoid quinine, quinidine, or fl uoxetine
Agrin defi ciency No response to pyridostigmine or amifampridine in one patient; partial response to ephedrine in a second patient
Use pyridostigmine with caution LRP4 defi ciency ..
Avoid pyridostigmine and amifampridine
MuSK defi ciency Variable response to amifampridine; good response to salbutamol in one patient [55] [56] [57] [58] Conventional doses of pyridostigmine can worsen symptoms Dok-7 defi ciency Salbutamol or ephedrine 24, 63 Avoid pyridostigmine Rapsyn defi ciency Pyridostigmine, amifampridine salbutamol 70 .. GFPT1, DAPGT1, ALG2 and ALG14 associated congenital myasthenic syndrome Pyridostigmine; amifampridine might confer additional benefi t [78] [79] [80] 83 ..
PREPL deletion syndrome
Pyridostigmine benefi cial in infancy 84 Old patients are refractory to pyridostigmine 84 Plectin defi ciency Refractory to pyridostigmine and amifampridine 2 ..
Defects in sodium channels
Pyridostigmine and acetazolamide 91 ..
MuSK=muscle-specifi c kinase. ··=no data available. Review will be that it cannot identify newly emerging CMS disease genes. However, in many patients it will obviate the need for more expensive whole-exome sequencing. More CMS disease genes are very likely to be discovered, but demonstration of pathogenicity associated with individual mutations will still be a necessity. This demonstration will take advantage of tried and true methods for gene expression and functional comparison of the wild type and mutant gene products. Clinicians armed with knowledge of the molecular mechanism behind the aberrant gene product will be in an advantageous position to formulate rational and individualised therapies for each form of CMS.
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